Abstract: A power monitor and management system includes an automatic modulation device, a monitoring device, multiple modules and an LAN (local area network) connected to the monitoring device and the modules to enable the monitoring device to communicate with the modules. The automatic modulation device determines a dominating module in according to registration sequences of the modules and subordinating modules and to modulate power of the dominating module and the subordinating modules as well as the overall power output in accordance with number of the modules.

Abstract: A prioritization is determined amongst a group of receivers for receiving signals transmitted from the wireless transmitter, without use of accurate channel state information. A signal is transmitted to each receiver based on an order that is determined by the prioritization. The transmitted signal can be encoded so that the receiver is able to receive the signal regardless of a channel state as between that receiver and the wireless transmitter.

Abstract: The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.

Abstract: A method for treatment of cancer by inhibiting the activity of histone deacetylase, comprising administering to a human in need of such treatment a composition containing a therapeutically effective amount of a gold(III) complex having the structural formula of or a pharmaceutically acceptable salt thereof, wherein: —R is selected from the group consisting of —OH, —CH2OH, C2H4OH, —C3H6OH or —C4H8OH; and X is independently a pharmaceutically acceptable counter-ion.

Abstract: The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.

Abstract: The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.

Abstract: A method for treatment of cancer by inhibiting the activity of histone deacetylase, comprising administering to a human in need of such treatment a composition containing a therapeutically effective amount of a gold(III) complex having the structural formula of or a pharmaceutically acceptable salt thereof, wherein: —R is selected from the group consisting of —OH, —CH2OH, C2H4OH, —C3H6OH or —C4H8OH; and X is independently a pharmaceutically acceptable counter-ion.

Abstract: The present invention relates to a pharmaceutical composition comprising one or more of the following ruthenium oxalato compounds I, II, III and IV as an active ingredient. The pharmaceutical composition can be used for the treatment of viral-infected patients or prophylactic treatment of patients at risk from viral infection.

Abstract: Gold(III) phosphine complexes [Aum(CNC)mL]n+ (where HCNCH=2,6-diphenylpyridine) and their use as anti-tumor agents are disclosed. Notable results for the appearance of new potential anti-tumor application of these gold(III) complexes are reported. The described complexes show promising cytotoxic properties toward cancer cells in both in vitro and in vivo studies.

Abstract: Gold(III)phosphine complexes [Aum(CNC)mL]n+ (where HCNCH=2,6-diphenylpyridine) and their use as anti-tumor agents are disclosed. Notable results for the appearance of new potential anti-tumor application of these gold(III) complexes are reported. The described complexes show promising cytotoxic properties toward cancer cells in both in vitro and in vivo studies.

Abstract: The present invention relates to a pharmaceutical composition comprising one or more of the following ruthenium oxalato compounds I, II, III and IV as an active ingredient. The pharmaceutical composition can be used for the treatment of viral-infected patients or prophylactic treatment of patients at risk from viral infection.

Abstract: A paper feeder comprises a control unit; a pair of side plates; a feed module having two or more separate feed rollers; a transport module having two or more separate transport rollers; a pusher module having a belt assembly and at least one pusher roller disposed under the belt assembly, the belt assembly further having two or more parallel shafts and two or more belts each having a protrusion and fitted on the shafts, the protrusions corresponding to each other; a first driving mechanism having a first motor and a first transmission mechanism, the first motor being connected to the first transmission mechanism which is in turn connected to at least one of the feed rollers; a second driving mechanism having a second motor and a second transmission mechanism, the second motor being connected to the second transmission mechanism which is in turn connected to at least one of the pusher rollers; a third driving mechanism having a third motor and a third transmission mechanism, the third motor being connected to